PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-85.48%
Both companies show declining cash positions (-85.48% vs CRVO's -87.48%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-85.48%
Similar yoy growth to CRVO's -87.48%. Walter Schloss would note comparable liquidity expansions. Examine capital usage strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2826.88%
≥ 1.5x CRVO's 74.24%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2826.88%
≥ 1.5x CRVO's 9.82%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-6.18%
Less than half of CRVO's 57.90%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.20%
1.25-1.5x CRVO's 8.14%. Martin Whitman is wary of bigger short-term burdens.
3.22%
Higher Long-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.22%
Higher Total Non-Current Liabilities Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
5.38%
Similar yoy to CRVO's 6.90%. Walter Schloss sees parallel expansions in total liabilities.
No Data
No Data available this quarter, please select a different quarter.
10.06%
≥ 1.5x CRVO's 1.60%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
26.94%
1.25-1.5x CRVO's 18.46%. Bruce Berkowitz notes an above-average equity expansion.
2826.88%
≥ 1.5x CRVO's 9.82%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
3.22%
Less than half of CRVO's -3.56%. David Dodd sees less overall debt expansion vs. competitor.
4.70%
Less than half of CRVO's 19.37%. David Dodd sees better deleveraging or stronger cash buildup than competitor.